Orion and Johns Hopkins University Sign Licensing Agreement
Posted on: Thursday, 12 June 2008, 12:00 CDT
Orion Genomics has entered into a worldwide exclusive license agreement with the Johns Hopkins University to commercialize products that identify patients at risk for colorectal cancer.
The license is based on a suite of issued and pending Johns Hopkins University patents covering imprinting abnormalities of the insulin-like growth factor 2 gene (IGF2).
Orion's simple blood-based risk assessment test is being designed to identify people who carry the IGF2 biomarker and may be at increased risk of developing sporadic colorectal cancer. It is expected that the test will enable at-risk patients to undergo screening for colorectal cancer significantly earlier, allowing physicians to remove precancerous polyps and prevent future colon cancer.
Nathan Lakey, president and CEO of Orion, said: "Our colorectal cancer risk test has the potential to save lives by identifying a group of high risk individuals who are likely to develop colorectal cancer at a younger age, and who should undergo colonoscopy screening 10 to 20 years earlier than the age that is currently recommended."
Source: Datamonitor
Related Articles
- The Risks Behind Colorectal Cancer
- ScreenCancer Adds InSure(R) FIT(TM) Colorectal Cancer Screening Test to European Cancer Screening Program
- Previstage(TM) GCC Colorectal Cancer Staging Test Featured in Expert Reviews Article
- DiagnoCure Wins US Approval for Colorectal Cancer Staging Test
- C-Reactive Protein and Risk for Colorectal Cancer/IN RESPONSE
- Aspirin May Cut Risk of Colorectal Cancer
- Increased Vitamin B Consumption Reduces Women's Risk of Colorectal Cancer
- C-Reactive Protein Levels Are Not Associated With Increased Risk for Colorectal Cancer in Women
- Drinking Milk May Lower Risk of Colorectal Cancer
- Know the Risks for Colorectal Cancer
 |
 |
User Comments (0)
RSS Feeds